NCT00232362: Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus |
|
|
| Withdrawn | 1 | 0 | US | Pioglitazone (Actos), Anti-diabetic agent other than pioglitazone or rosiglitazone | Texas Tech University Health Sciences Center | Type 2 Diabetes Mellitus | | 06/08 | | |
| Completed | 1 | 211 | US | Comparator: sitagliptin phosphate, Comparator: pioglitazone, Comparator: placebo to pioglitazone, Comparator: placebo to sitagliptin | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus (T2DM) | 02/09 | 02/09 | | |
NCT01088594: A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers |
|
|
| Completed | 1 | 12 | Europe | pioglitazone/rosiglitazone/placebo, rosiglitazone/pioglitazone/placebo, placebo/pioglitazone/rosiglitazone, pioglitazone/placebo/rosiglitazone, rosiglitazone/placebo/pioglitazone, placebo/rosiglitazone/pioglitazone | Solvay Pharmaceuticals | Type 2 Diabetes Mellitus | 03/10 | 03/10 | | |
NCT02753803: Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg |
|
|
| Completed | 1 | 36 | RoW | Evogliptin, Pioglitazone, Evogliptin+Pioglitazone, Suganon, Actos, Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Pioglitazone, Pioglitazone, Evogliptin+Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Evogliptin, Pioglitazone, Evogliptin+Pioglitazone, Pioglitazone, Evogliptin | Dong-A ST Co., Ltd. | Type 2 Diabetes | 10/16 | 03/17 | | |
